Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
6.14
+0.12 (1.99%)
Oct 27, 2026, 10:20 AM EDT - Market open
Myriad Genetics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Myriad Genetics stock has a consensus rating of "Hold" and an average price target of $4.49. The average 1-year stock price forecast is 26.92% lower than the current stock price, while the lowest is $2.50 (-59.28%) and the highest is $8.00 (+30.29%).
Price Target: $4.49 (-26.92%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Myriad Genetics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 6 | 5 | 4 | 5 | 5 | 6 |
| Sell | 1 | 1 | 1 | 1 | 2 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 10 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Buy Reiterates $8 | Buy | Reiterates | $8 | +30.29% | Oct 22, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Reiterates $3.2 | Sell | Reiterates | $3.2 | -47.88% | Oct 21, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $4 → $4.5 | Hold | Maintains | $4 → $4.5 | -26.71% | Oct 13, 2026 |
Unknown Analyst UBS No rating | UBS | Hold Initiates $6 → $3.6 | Hold | Initiates | $6 → $3.6 | -41.37% | Sep 9, 2026 |
| Piper Sandler | Piper Sandler | Sell Downgrades $8.5 → $2 | Sell | Downgrades | $8.5 → $2 | -67.43% | Sep 1, 2026 |
Financial Forecast
Revenue This Year
778.47M
from 824.50M
Decreased by -5.58%
Revenue Next Year
822.17M
from 778.47M
Increased by 5.61%
EPS This Year
-0.74
from 0.06
EPS Next Year
-0.59
from -0.74
EPS and Forward PE are based on non-GAAP adjusted numbers.